Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy-proven prostate cancer.~2. Progressive, castration-resistant disease according to PCWG2 criteria.~3. Planned treatment with an androgen signaling inhibitor (e.g., abiraterone, enzalutamide, apalutamide (ARN-509)). Patients must not be receiving androgen signaling inhibitor at the time of the baseline MR scan. Combination treatment (e.g., androgen signaling inhibitor in conjunction with another systemic treatment) is allowed.~4. Presence of at least one target lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:~   * Soft tissue/visceral organ target lesions must measure at 1.5 cm in long axis diameter on CT or MRI.~  * Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify).~  * For patients with target lesion in prostate/prostatic bed:~     i. No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).~   ii. No prior local treatment to the selected lesion. Patients who have received prior radiation or ablative therapy to the prostate will be required to have biopsy-proven evidence of disease recurrence following completion of local therapy.~5. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.~6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.~7. Adequate organ function, including absolute neutrophil count (ANC) ≥ 1500 cells/µL, hemoglobin ≥ 9.0 gm/dL, platelets ≥ 75,000 cells/µL, creatinine \< 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min (by the Cockcroft Gault equation), bilirubin \<1.5x ULN (unless Gilbert's is suspected in which case total bilirubin \< 3 x ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 1.5x ULN.~8. For patients undergoing optional tumor biopsy:~   * No history of bleeding diathesis.~  * Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.~9. For patients with partners of childbearing potential, willing to use adequate contraception for one month after undergoing HP pyruvate infusion.~10. Patients must have prior bilateral orchiectomy or be on continuous luteinizing-hormone releasing hormone (LHRH) analogue therapy for the duration of study.~11. Castrate level of serum testosterone (\< 50 ng/dL) at study entry.~Exclusion Criteria:~1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.~2. Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.~3. Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.~4. Poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The addition of anti-hypertensives to control blood pressure is allowed.~5. Congestive heart failure or New York Heart Association (NYHA) status ≥ 2.~6. A history of clinically significant EKG abnormalities, including QT prolongation (QTcF \> 500 ms), a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.~7. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR imaging with hyperpolarized 13C pyruvate of men with CRPC (Type: EXPERIMENTAL): 75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).